[go: up one dir, main page]

MX2022007160A - Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad. - Google Patents

Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad.

Info

Publication number
MX2022007160A
MX2022007160A MX2022007160A MX2022007160A MX2022007160A MX 2022007160 A MX2022007160 A MX 2022007160A MX 2022007160 A MX2022007160 A MX 2022007160A MX 2022007160 A MX2022007160 A MX 2022007160A MX 2022007160 A MX2022007160 A MX 2022007160A
Authority
MX
Mexico
Prior art keywords
dosage form
prevention
treatment
coating layer
disease
Prior art date
Application number
MX2022007160A
Other languages
English (en)
Inventor
Vinay Jain
Ashish Guha
Shraddha Joshi
Priyanka Haksar
Umesh Kapale
Nilam Bharambe
Original Assignee
Evonik Operations Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Operations Gmbh filed Critical Evonik Operations Gmbh
Publication of MX2022007160A publication Critical patent/MX2022007160A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a una forma de dosificación, que comprende un ingrediente biológicamente activo para usarse en el tratamiento o prevención de una enfermedad en el cuerpo animal o humano, cuyo tratamiento o prevención requiera la liberación del 50% o más del ingrediente biológicamente activo en el intestino delgado dentro del intervalo de pH de 3 a 5.5, en donde la forma de dosificación comprende: a) un núcleo, que comprende el ingrediente biológicamente activo, b) una capa de revestimiento intermedio (ICL) sobre o por encima del núcleo, que comprende un agente alcalino, y c) una capa de revestimiento entérico (ECL) sobre o por encima de la capa de revestimiento intermedio que comprende un polímero entérico, en donde la relación del agente alcalino con respecto al polímero entérico en la forma de dosificación es del 5 al 95% cuando se calcula por medio de la fórmula: (ver Fórmula) y en donde la capa de revestimiento intermedio (ICL) tiene un espesor de aproximadamente 22 µm o más.
MX2022007160A 2019-12-11 2020-09-17 Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad. MX2022007160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941051211 2019-12-11
PCT/EP2020/075961 WO2021115649A1 (en) 2019-12-11 2020-09-17 Dosage form for use in treating or preventing of a disease

Publications (1)

Publication Number Publication Date
MX2022007160A true MX2022007160A (es) 2022-07-11

Family

ID=72560601

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007160A MX2022007160A (es) 2019-12-11 2020-09-17 Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad.

Country Status (10)

Country Link
US (1) US20230048354A1 (es)
EP (1) EP4072531A1 (es)
JP (1) JP7625601B2 (es)
KR (1) KR20220113941A (es)
CN (1) CN114828832A (es)
BR (1) BR112022011295A2 (es)
CA (1) CA3160862A1 (es)
IL (1) IL293653A (es)
MX (1) MX2022007160A (es)
WO (1) WO2021115649A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE066609T2 (hu) 2019-12-11 2024-08-28 Evonik Operations Gmbh Adagolási forma betegség kezelésében vagy megelõzésében történõ alkalmazásra
US20250177315A1 (en) * 2022-03-15 2025-06-05 Evonik Operations Gmbh Pre-functionalized hard shell capsule with accelerated drug release at ph value 5 to 5.5
EP4382099A1 (en) * 2022-12-05 2024-06-12 ADD Advanced Drug Delivery Technologies, Ltd. Drug loaded modified release pellets

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE19626045C2 (de) 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US20050214372A1 (en) 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
JP2009519334A (ja) 2005-12-20 2009-05-14 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール経口崩壊錠剤
KR101443943B1 (ko) 2007-05-07 2014-10-07 에보니크 룀 게엠베하 가속된 약물 방출을 갖는 장용 코팅을 포함하는 고체 투여 형태
WO2011140446A2 (en) * 2010-05-06 2011-11-10 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations
DE102010052847A1 (de) * 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
CN102626398A (zh) * 2012-04-18 2012-08-08 上海腾瑞制药有限公司 一种泮托拉唑钠肠溶片及其制备方法
HUE061861T2 (hu) * 2015-07-17 2023-08-28 Be Pharbel Mfg Többrétegû, gyógyászatilag aktív vegyületet leadó mikroszemcsék folyékony dózisformában
CN105640915A (zh) * 2016-03-02 2016-06-08 吉林修正药业新药开发有限公司 一种雷贝拉唑钠肠溶片及其制备工艺
HUE066609T2 (hu) * 2019-12-11 2024-08-28 Evonik Operations Gmbh Adagolási forma betegség kezelésében vagy megelõzésében történõ alkalmazásra

Also Published As

Publication number Publication date
JP7625601B2 (ja) 2025-02-03
KR20220113941A (ko) 2022-08-17
WO2021115649A1 (en) 2021-06-17
US20230048354A1 (en) 2023-02-16
CN114828832A (zh) 2022-07-29
JP2023505883A (ja) 2023-02-13
IL293653A (en) 2022-08-01
CA3160862A1 (en) 2021-06-17
EP4072531A1 (en) 2022-10-19
BR112022011295A2 (pt) 2022-09-06

Similar Documents

Publication Publication Date Title
MX2022007160A (es) Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad.
MX2022007162A (es) Forma de dosificacion que comprende un agente alcalino y una capa de revestimiento enterico.
ECSP21051833A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
BR0306513A (pt) tampão com medicamento
CO6511199A2 (es) Combinación de un agente quimioterapéutico y un inhibidor del sistema tgf- beta
CO5611101A2 (es) Artefactos medicos resistentes a la infeccion
CY1107615T1 (el) Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων
GT200200138A (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
MX2009012030A (es) Formas farmacéuticas sólidas compuestas de un recubrimiento enterico con liberación acelerada del medicamento.
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
CR20170142A (es) Composiciones farmacéuticas resistentes al abuso
MX2017015247A (es) Metodos y composiciones para modular la microbiota intestinal y para manejar el peso.
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
CL2011002650A1 (es) Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson.
ES2530731T3 (es) Dispositivos médicos que contienen nitroprusiato y agentes antimicrobianos
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
UY38345A (es) Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g
CO2022000426A2 (es) Inhibidores de calicreína plasmática
MX2018007048A (es) Composiciones para el cuidado bucal que comprenden al menos un copolimero de fosfato / acrilato y al menos un ingrediente activo cationico.
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
BR112015032284A2 (pt) dispositivo médico compreendendo colágeno-vi
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX2022007161A (es) Forma de dosificacion para usarse en el tratamiento o prevencion de una enfermedad.
UY31059A1 (es) Formulaciones de aminoacido n-halogenado
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido